Category: Pharma, Life Sciences & Med Tech Players
-
âThe future of medicine and diagnosticsâ: behind the patent enforcement strategy of biotech tools company SeerÂ
Seerâs VP of Legal, George Fox, discusses the challenges that its patent portfolio has recently overcome, and the enforcement campaign it has launched in the U.S.Â
-
Malikie Innovations sets sights on medical device segment with latest U.S. complaint targeting Abbott
The heir to the BlackBerry patent portfolio appears to be testing the waters in the multibillion-dollar market for connected medical devices.
-
Moderna calls itself the âtrue innovatorâ in response to CureVac mRNA patent lawsuit, cites broken non-assert promise
Moderna has filed a response to CureVacâs mRNA patent suit, denying infringement, attacking the validity of all 10 patents, and calling the lawsuit âultimately a meritless attempt to claim success for work it never didâ.
-
Awaiting potential $1.3B Moderna payout, Arbutus expands Covid-19 patent fight to Pfizer, BioNTech in Canada and UPC
Arbutus and Genevant have filed new lawsuits against Pfizer and BioNTech in Canada and the UPC over lipid nanoparticle patents, days after collecting $178 million from their Moderna settlement.
-
Covid-19 vaccine makers Moderna and Pfizer hit with Sanofi suits over mRNA delivery tech
Sanofi and Translate Bio effectively abandoned their own Covid-19 vaccine effort in 2021 after the former acquired the latter.
-
Munich court finds Illumina infringes Element sequencing patent, orders injunction and product recall
The Munich I Regional Court has found Illumina liable for infringing an Element Biosciences sequencing patent, ordering an injunction, a product recall, and damages, a rare loss for the U.S. sequencing giant.
-
Federal Circuit upholds decision to throw out $107.5M patent infringement verdict against AstraZeneca
The precedential decision, confirming the invalidation of two of Pfizer subsidiary Wyethâs cancer drug-related patents, held that the plaintiff not only failed to rebut evidence on certain issues, but its own experts agreed against it.
-
UPC Munich LD revokes Promosomeâs mRNA patent, dismisses infringement claims against BioNTech, Pfizer over Comirnaty
The UPCâs Munich LD revoked Promosomeâs mRNA patent as invalid over prior art and found no infringement by BioNTech and Pfizerâs Comirnaty vaccine, ending the dispute.
-
UPC CoA rejects Guardantâs provisional measures appeal against Sophia Genetics on urgency grounds; reverses added matter finding
The UPCâs CoA has dismissed Guardant Healthâs provisional measures appeal over a cancer-detection patent against Sophia Genetics, finding an unexplained three-month gap fatal to urgency, though it reversed the added matter ruling below.
-
Federal Circuit applies Third Circuit law to vacate District of Delaware’s waiver of preliminary injunction bond
The district court made the rare decision to waive Otsuka Pharmaceutical’s requirement to post a bond after granting it a preliminary injunction against Hetero Labs’ generic competitor.